Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Marshall

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Trauma and Acute Care Surgery|April 25, 2022
Impact of time to surgery on mortality in hypotensive patients with noncompressible torso hemorrhage: An AAST multicenter, prospective studyJuan Duchesne, Kevin Slaughter, Ivan Puente, et al.
Journal of Medicinal Chemistry|July 26, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306Janek Szychowski, Robert Papp, Evelyne Dietrich, et al.
Plos One|May 25, 2012
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia veraManfred Kraus, Yuxun Wang, Dan Aleksandrowicz, et al.
Journal of Medicinal Chemistry|October 29, 2021
Discovery of <b>MK-4688</b>: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionMichael H Reutershan, Michelle R Machacek, Michael D Altman, et al.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Journal of Medicinal Chemistry|May 26, 2011
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancerJason D Katz, James P Jewell, David J Guerin, et al.
Nature|April 21, 2022
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibitionDavid Gallo, Jordan T F Young, Jimmy Fourtounis, et al.
Journal of Medicinal Chemistry|May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 InhibitorFrédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.
Blood|November 22, 2019
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasmsLanzhu Yue, Vasundhara Sharma, Nathan P Horvat, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Trauma and Acute Care Surgery|April 25, 2022
Impact of time to surgery on mortality in hypotensive patients with noncompressible torso hemorrhage: An AAST multicenter, prospective studyJuan Duchesne, Kevin Slaughter, Ivan Puente, et al.
Journal of Medicinal Chemistry|July 26, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306Janek Szychowski, Robert Papp, Evelyne Dietrich, et al.
Plos One|May 25, 2012
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia veraManfred Kraus, Yuxun Wang, Dan Aleksandrowicz, et al.
Journal of Medicinal Chemistry|October 29, 2021
Discovery of <b>MK-4688</b>: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionMichael H Reutershan, Michelle R Machacek, Michael D Altman, et al.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Journal of Medicinal Chemistry|May 26, 2011
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancerJason D Katz, James P Jewell, David J Guerin, et al.
Nature|April 21, 2022
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibitionDavid Gallo, Jordan T F Young, Jimmy Fourtounis, et al.
Journal of Medicinal Chemistry|May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 InhibitorFrédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.
Blood|November 22, 2019
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasmsLanzhu Yue, Vasundhara Sharma, Nathan P Horvat, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Pageof 6